AR046833A1 - Anticuerpos anti-interleuquina-10 - Google Patents

Anticuerpos anti-interleuquina-10

Info

Publication number
AR046833A1
AR046833A1 ARP040104114A ARP040104114A AR046833A1 AR 046833 A1 AR046833 A1 AR 046833A1 AR P040104114 A ARP040104114 A AR P040104114A AR P040104114 A ARP040104114 A AR P040104114A AR 046833 A1 AR046833 A1 AR 046833A1
Authority
AR
Argentina
Prior art keywords
seq
amino acid
acid sequence
entirety
structure region
Prior art date
Application number
ARP040104114A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR046833A1 publication Critical patent/AR046833A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments

Abstract

Los métodos y composiciones proporcionados se refieren, en general, a anticuerpos específicos contra IL-10 y sus usos. Más específicamente, las composiciones de anticuerpos específicos contra IL-10 humanizados y métodos para utilizar ese tipo de anticuerpos en la modulación de la actividad biológica de IL-10, particularmente en trastornos autoinmunes e inmunopatología mediada por un patógeno. Además se proporcionan ácidos nucleicos que codifican dichos polipéptidos así como vectores, células huésped y métodos para producirlas. Reivindicación 1: Una molécula de anticuerpo recombinante humanizado que une IL-10 o su fragmento, que comprende: por lo menos una región variable de cadena liviana de anticuerpo, o su fragmento de unión, que comprende un polipéptido que tiene por lo menos una secuencia de aminoácidos seleccionada del grupo formado por SEC ID NO: 1 en CDR1, SEC ID NO: 2 en CDR2, SEC ID NO: 3 en CDR3; y una región de estructura, en donde la secuencia de aminoácidos de la región de estructura es de su totalidad o sustancialmente en su totalidad una secuencia de aminoácidos de inmunoglobina humana; y por lo menos una región variable de cadena pesada de anticuerpo, o su fragmento de unión, que comprende un polipéptido que tiene por lo menos una secuencia de aminoácidos seleccionada del grupo formado por SEC ID NO: 6 en CDR1, SEC ID NO: 7 en CDR2, y SEC ID NO: 8 en CDR3; y una región de estructura, en donde la secuencia de aminoácidos de la región de estructura es en su totalidad o sustancialmente en su totalidad una secuencia de aminoácidos de inmunoglobina humana.
ARP040104114A 2003-11-10 2004-11-08 Anticuerpos anti-interleuquina-10 AR046833A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51899903P 2003-11-10 2003-11-10

Publications (1)

Publication Number Publication Date
AR046833A1 true AR046833A1 (es) 2005-12-28

Family

ID=34590335

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040104114A AR046833A1 (es) 2003-11-10 2004-11-08 Anticuerpos anti-interleuquina-10
ARP090104950A AR074779A2 (es) 2003-11-10 2009-12-17 Anticuerpos contra interleuquina -10
ARP090104951A AR074780A2 (es) 2003-11-10 2009-12-17 Metodo para humanizar anticuerpos contra interleuquina 10 (il-10)

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP090104950A AR074779A2 (es) 2003-11-10 2009-12-17 Anticuerpos contra interleuquina -10
ARP090104951A AR074780A2 (es) 2003-11-10 2009-12-17 Metodo para humanizar anticuerpos contra interleuquina 10 (il-10)

Country Status (26)

Country Link
US (5) US20050101770A1 (es)
EP (4) EP2128175A1 (es)
JP (4) JP4762148B2 (es)
KR (3) KR20120025618A (es)
CN (2) CN102010471A (es)
AR (3) AR046833A1 (es)
AT (1) ATE440867T1 (es)
AU (2) AU2004290044B2 (es)
CA (2) CA2812856A1 (es)
CY (1) CY1110557T1 (es)
DE (1) DE602004022855D1 (es)
DK (1) DK1694705T3 (es)
ES (1) ES2329907T3 (es)
HK (1) HK1087722A1 (es)
HR (1) HRP20090517T1 (es)
IL (3) IL175523A (es)
NO (1) NO20062672L (es)
NZ (1) NZ546632A (es)
PE (3) PE20090047A1 (es)
PL (1) PL1694705T3 (es)
PT (1) PT1694705E (es)
RS (1) RS51180B (es)
SG (1) SG155205A1 (es)
SI (1) SI1694705T1 (es)
WO (2) WO2005047324A2 (es)
ZA (1) ZA200603681B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404359A2 (en) * 2000-12-07 2004-04-07 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
EP1490101A4 (en) * 2002-03-05 2006-09-20 Univ Texas METHODS OF IMPROVING INDUCTION OF IMMUNE RESPONSE INVOLVING MDA-7
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
BRPI0418311B8 (pt) * 2004-02-23 2021-06-22 Synthes Ag parafuso de osso
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
WO2006086798A2 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving mda-7 for the treatment of cancer
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
EP1931710B1 (en) 2005-08-31 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
PL2066695T3 (pl) * 2006-09-05 2013-08-30 Lilly Co Eli Przeciwciała przeciwko miostatynie
EP2628752A1 (en) 2006-12-14 2013-08-21 Merck Sharp & Dohme Corp. Engineered anti-TSLP antibody
CN101631773A (zh) 2006-12-22 2010-01-20 先灵公司 治疗或预防hcv和相关病毒感染的4,5-环化吲哚衍生物
AU2007339386B8 (en) * 2006-12-22 2013-12-05 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
WO2008136815A2 (en) 2006-12-22 2008-11-13 Schering Corporation 5, 6-ring annulated indole derivatives and use thereof
BRPI0720841A2 (pt) 2006-12-22 2014-03-04 Schering Corp Anticorpos para cd200r
US20100111966A1 (en) 2007-02-23 2010-05-06 Schering Corporation Engineered anti-il-23p19 antibodies
CA2678749C (en) 2007-02-23 2018-03-13 Schering Corporation Engineered anti-il-23p19 antibodies
EP2395025A1 (en) 2007-02-28 2011-12-14 Schering Corporation Engineered Anti-IL-23R Antibodies
TW200911807A (en) * 2007-08-29 2009-03-16 Schering Corp 2,3-substituted azaindole derivatives and methods of use thereof
BRPI0816116A2 (pt) * 2007-08-29 2015-03-03 Schering Corp Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
CN101821252A (zh) 2007-08-29 2010-09-01 先灵公司 取代的吲哚衍生物及其使用方法
JP5249344B2 (ja) * 2007-11-16 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション ヘテロ環の３位が置換されたインドール誘導体およびその使用
CA2705587A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
EP2303893B1 (en) * 2008-06-13 2016-12-07 Merck Sharp & Dohme Corp. Tricyclic indole derivatives
EP2331579B1 (en) * 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies
MX2011008843A (es) * 2009-02-23 2011-12-14 Glenmark Pharmaceuticals Sa Anticuerpos humanizados que se unen a cd19 y sus usos.
WO2010138791A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
LT3023438T (lt) 2009-09-03 2020-05-11 Merck Sharp & Dohme Corp. Anti-gitr antikūnai
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
CN102711829B (zh) * 2009-11-30 2016-03-16 生物测试股份公司 治疗***性红斑狼疮(sle)的人源化抗il-10抗体
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
PE20130062A1 (es) 2010-03-09 2013-02-28 Merck Sharp & Dohme Compuestos de sililo triciclicos fusionados para el tratamiento de enfermedades virales
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012050848A1 (en) 2010-09-29 2012-04-19 Schering Corporation Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
RS57502B1 (sr) * 2010-11-23 2018-10-31 Glaxo Group Ltd Antigen-vezujući proteini za onkostatin m (osm)
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
JP2014515023A (ja) 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション ２’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
CN102250243B (zh) * 2011-07-01 2013-08-28 华绍炳 抗白细胞介素-15抗体
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US9512405B2 (en) 2011-12-14 2016-12-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Non-enzymatic method for isolating human adipose-derived stromal stem cells
KR102207859B1 (ko) 2013-03-15 2021-01-27 메모리얼 슬로안 케터링 캔서 센터 고 친화도 항-gd2 항체
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
CN105277638A (zh) * 2014-07-22 2016-01-27 沈鹤霄 一种单克隆抗体IgG质谱测序方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
RU2017145559A (ru) * 2015-05-29 2019-07-03 Мерк Шарп И Доум Корп. Комбинация антитела к il-10 и олигонуклеотида типа cpg-c для лечения рака
EP3302501B1 (en) 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
US20190010224A1 (en) * 2015-12-22 2019-01-10 Merck Sharp & Dohme Corp. Formulations of engineered anti-il-10 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3060581A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
EP3697425A1 (en) 2017-10-18 2020-08-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
WO2019179420A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-tim-3 antibodies
IL302871A (en) 2020-11-18 2023-07-01 Astrazeneca Ab Saving steroids

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US6312680B1 (en) 1990-06-29 2001-11-06 Timothy R. Mosmann Methods of treatment using cytokine synthesis inhibitory factor
ES2206447T3 (es) * 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
HU224437B1 (hu) * 1991-08-06 2005-09-28 Schering Corp. Eljárás interleukin-10 analógokat vagy antagonistákat tartalmazó endotoxin- vagy szuperantigén-indukált toxicitás kezelésére szolgáló gyógyszerkészítmények előállítására
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
WO1994004180A2 (en) * 1992-08-20 1994-03-03 Schering Corporation Novel uses of il-4 and/or il-10, and antibodies against the same
DE19529026C2 (de) * 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
AU2001233027A1 (en) * 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2004006955A1 (en) * 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
CA2463927A1 (en) * 2001-10-16 2003-04-24 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.

Also Published As

Publication number Publication date
US8624013B2 (en) 2014-01-07
AR074779A2 (es) 2011-02-09
AU2004290044B2 (en) 2010-11-18
JP2011087590A (ja) 2011-05-06
KR20120025618A (ko) 2012-03-15
PL1694705T3 (pl) 2010-02-26
ATE440867T1 (de) 2009-09-15
CN100595212C (zh) 2010-03-24
JP4762148B2 (ja) 2011-08-31
CA2545255C (en) 2013-06-25
WO2005047326A3 (en) 2005-12-22
PE20090047A1 (es) 2009-01-26
PE20090046A1 (es) 2009-01-26
EP2123678A1 (en) 2009-11-25
PT1694705E (pt) 2009-11-30
CA2812856A1 (en) 2005-05-26
DK1694705T3 (da) 2009-12-07
JP2014014361A (ja) 2014-01-30
US20140112919A1 (en) 2014-04-24
AU2004290044A1 (en) 2005-05-26
AU2011200606B2 (en) 2012-05-10
IL202681A0 (en) 2010-06-30
KR20120023858A (ko) 2012-03-13
HRP20090517T1 (en) 2009-10-31
CY1110557T1 (el) 2015-04-29
EP1694705A2 (en) 2006-08-30
IL202682A0 (en) 2010-06-30
KR101175055B1 (ko) 2012-08-22
EP2128175A1 (en) 2009-12-02
US20120282253A1 (en) 2012-11-08
CN1906213A (zh) 2007-01-31
HK1087722A1 (en) 2006-10-20
AR074780A2 (es) 2011-02-09
NO20062672L (no) 2006-06-09
EP1694705B1 (en) 2009-08-26
KR20060120093A (ko) 2006-11-24
ZA200603681B (en) 2010-01-27
IL175523A0 (en) 2006-09-05
US20100203049A1 (en) 2010-08-12
EP2292661A2 (en) 2011-03-09
RS51180B (sr) 2010-10-31
WO2005047324A2 (en) 2005-05-26
US20050101770A1 (en) 2005-05-12
PE20050925A1 (es) 2005-11-29
CN102010471A (zh) 2011-04-13
US7662379B2 (en) 2010-02-16
DE602004022855D1 (de) 2009-10-08
SG155205A1 (en) 2009-09-30
AU2011200606A1 (en) 2011-03-03
JP2008500020A (ja) 2008-01-10
ES2329907T3 (es) 2009-12-02
NZ546632A (en) 2009-07-31
CA2545255A1 (en) 2006-05-05
EP2292661A3 (en) 2011-06-22
US8226947B2 (en) 2012-07-24
IL175523A (en) 2011-01-31
WO2005047326A2 (en) 2005-05-26
US20070178097A1 (en) 2007-08-02
JP2011062211A (ja) 2011-03-31
SI1694705T1 (sl) 2010-01-29
IL202681A (en) 2011-10-31

Similar Documents

Publication Publication Date Title
AR046833A1 (es) Anticuerpos anti-interleuquina-10
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
JP2022160698A (ja) 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
RU2505603C2 (ru) Антитело против рецептора il-6
PE20231067A1 (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
PE20190976A1 (es) Anticuerpos de union a cd3
EA202091710A1 (ru) Антитела против cd73 и способы их применения
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
SI2573121T1 (en) IL-4 and / or IL-13 binding antibodies and their uses
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
ES2124224T3 (es) Metodo para escrutar genotecas recombinantes.
RS54088B1 (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
AR058322A1 (es) Proteinas de union especificas de factores de crecimiento tipo insulina y usos de las mismas
TW200745164A (en) Gene recombination antibodies composition
AR047372A1 (es) Anticuerpos contra madcam
RU2017144098A (ru) Гетеродимеризованный полипептид
AR077088A1 (es) Proteinas biespecificas de union a antigeno
AR035119A1 (es) Anticuerpos humanos antagonistas anti-htnfsf13b
AR052285A1 (es) Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas
RU2003129528A (ru) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
RU2010136940A (ru) Антитела против альфа5-бета1 и их применение
CL2008003004A1 (es) Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos.
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
AR085091A1 (es) Anticuerpos anti-kit y sus usos
JP2019504617A5 (es)

Legal Events

Date Code Title Description
FG Grant, registration